Chembio Diagnostics Inc
NASDAQ:CEMI
Intrinsic Value
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. [ Read More ]
The intrinsic value of one CEMI stock under the Base Case scenario is 0.067 USD. Compared to the current market price of 0.455 USD, Chembio Diagnostics Inc is Overvalued by 85%.
Valuation Backtest
Chembio Diagnostics Inc
Run backtest to discover the historical profit from buying and selling CEMI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Chembio Diagnostics Inc
Current Assets | 48.5m |
Cash & Short-Term Investments | 18.2m |
Receivables | 18.7m |
Other Current Assets | 11.5m |
Non-Current Assets | 14.2m |
PP&E | 13.7m |
Other Non-Current Assets | 434.9k |
Current Liabilities | 39.3m |
Accounts Payable | 3.3m |
Accrued Liabilities | 17.3m |
Other Current Liabilities | 18.7m |
Non-Current Liabilities | 5.5m |
Long-Term Debt | 86.9k |
Other Non-Current Liabilities | 5.4m |
Earnings Waterfall
Chembio Diagnostics Inc
Revenue
|
49.5m
USD
|
Cost of Revenue
|
-38.6m
USD
|
Gross Profit
|
10.9m
USD
|
Operating Expenses
|
-31.3m
USD
|
Operating Income
|
-20.4m
USD
|
Other Expenses
|
-2.9m
USD
|
Net Income
|
-23.3m
USD
|
Free Cash Flow Analysis
Chembio Diagnostics Inc
What is Free Cash Flow?
CEMI Profitability Score
Profitability Due Diligence
Chembio Diagnostics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Chembio Diagnostics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
CEMI Solvency Score
Solvency Due Diligence
Chembio Diagnostics Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Chembio Diagnostics Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CEMI Price Targets Summary
Chembio Diagnostics Inc
Ownership
CEMI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CEMI Price
Chembio Diagnostics Inc
Average Annual Return | -33.14% |
Standard Deviation of Annual Returns | 43.49% |
Max Drawdown | -99% |
Market Capitalization | 16.7m USD |
Shares Outstanding | 36 725 900 |
Percentage of Shares Shorted | 0.82% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. The company is headquartered in Hauppauge, New York and currently employs 337 full-time employees. The company went IPO on 2000-10-18. Its product portfolio is based upon its DPP technology, a diagnostic platform that provides results in 15 to 20 minutes using fingertip blood, nasal swabs, and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as sexually transmitted infections (STIs) and human immunodeficiency virus (HIV), gastroenterology, and women's health. Its products include COVID-19 Antibody Test System, COVID-19 Antigen Test System, COVID-19 and Influenza Respiratory Antigen Panel Test System and HIV-Syphilis Diagnostic Test Systems, among others. The company is also targeting lateral flow test solutions for infectious diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one CEMI stock under the Base Case scenario is 0.067 USD.
Compared to the current market price of 0.455 USD, Chembio Diagnostics Inc is Overvalued by 85%.